American science is at a crossroads, but these extraordinary people, with their passion for knowledge and their dedication to our competitive future, are building its next chapter.
Dr. Joel Neal presents CHRYSALIS-2 data at ASCO 2026, highlighting a 3.5-year median survival and toxicity management for atypical EGFR-mutant NSCLC. Dr. Sara Tolaney discusses the ASCENT-04 trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results